Lymphoma, Leukemia Patients Sought for Trial of MoAb

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

BOSTON--Researchers at New England Deaconess Hospital are seeking patients with Hodgkin's disease, non-Hodgkin's lymphoma, acute myelogenous leukemia (AML), and chronic myelogenous leukemia (CML) for an FDA-sponsored study of a humanized anti-Tac (interleukin-2 receptor) monoclonal antibody. The phase Ib/II multidose trial will study tolerance, therapeutic efficacy, and biological efficacy.

BOSTON--Researchers at New England Deaconess Hospital are seekingpatients with Hodgkin's disease, non-Hodgkin's lymphoma, acutemyelogenous leukemia (AML), and chronic myelogenous leukemia (CML)for an FDA-sponsored study of a humanized anti-Tac (interleukin-2receptor) monoclonal antibody. The phase Ib/II multidose trialwill study tolerance, therapeutic efficacy, and biological efficacy.

The protocol (92-0205-34) calls for patients over the age of 18with a life expectancy greater than 2 months and confirmed Tacon malignant cells, except for Hodgkin's disease patients, forwhich all R-S (Reed-Sternberg) cells are Tac-positive. Also, patientsmust be able to have continuous local access for 1 month.

Hodgkin's disease patients (25 to be enrolled) must have failedfirst-line therapy and one salvage attempt. Non-Hodgkin's lymphomapatients with aggressive disease must have failed first-line therapy;if indolent, any patient is eligible. All CML patients (eightto be enrolled) are eligible. AML patients (eight to be enrolled)must have failed first-line therapy or be in first or later relapse.

For more information, contact Dan Hagg, New England DeaconessHospital, 21-27 Burlington Avenue, 5th Floor, Boston, MA 02215.Phone: 617-632-0316.

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content